Last reviewed · How we verify
OTX-CSI
At a glance
| Generic name | OTX-CSI |
|---|---|
| Sponsor | Ocular Therapeutix, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OTX-CSI CI brief — competitive landscape report
- OTX-CSI updates RSS · CI watch RSS
- Ocular Therapeutix, Inc. portfolio CI